PIOGLITAZONE HYDROCHLORIDE (pioglitazone) by Takeda is peroxisome proliferator-activated receptor alpha agonists [moa]. Approved for type 2 diabetes mellitus in multiple clinical settings, type 2 diabetes mellitus. First approved in 2018.
Drug data last refreshed 20h ago
Peroxisome Proliferator-activated Receptor alpha Agonists
Peroxisome Proliferator Receptor alpha Agonist
Worked on PIOGLITAZONE HYDROCHLORIDE at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Effects of Pioglitazone in Calcific Aortic Valve Disease